PrimeRFP SCOUT · Federal Contract Profile

Actelion Pharmaceuticals Us (H5BMHLMMNA28)Federal contracts · 1 recompete

Actelion Pharmaceuticals Us holds $5.4M in federal volume across 106 award actions, with 59% at Department of Veterans Affairs (VA). SCOUT tracks 1 incumbent recompete — an estimated $407K returning to market over the next 24 months (Low exposure). Primary work: Pharmaceutical Preparation (100% prime). Obligations are down 50% year over year.

$5.4M
Federal Volume
1
Recompetes (24mo)
VA
Top Agency · 59% firm-wide
106
Award Actions

Choose one — this changes what we ask next

Score my firm against Actelion Pharmaceuticals Us

One email. We send the overlap and watch their recompetes.

Choose one — this changes what we ask next

Data through · refreshed monthly · window Sep 2025 – Sep 2026

Why are you looking at Actelion Pharmaceuticals Us?

Score my firm against Actelion Pharmaceuticals Us

One email. We send the overlap and watch their recompetes.

What they do

Capability

Service lines

PHARMACEUTICAL PREPARATION MANUFACTURING

Work mix: 100% prime · 0% sub · primary NAICS 325412 / PSC 6505 DRUGS AND BIOLOGICALS

Where they win

2 agencies
% of firm-wide obligated ($5.4M) · all agencies

Recompete exposure: Low · 1 in 24mo

Actelion Pharmaceuticals Us has an estimated $407K in contracts returning to market over the next 24 months.

Recompete exposure & trajectory

Recompete exposure

Low

Actelion Pharmaceuticals Us has an estimated $407K in contracts returning to market over the next 24 months. 1 within 6 months ($407K).

Trajectory
▼ Consolidating-50% YoYFY2025 vs FY2024
'23
'24
'25
“After 35 years in federal contracting, I've seen what separates the firms that win from the ones that wonder why they lost. What SCOUT does is put the kind of competitive and market intelligence in front of BD teams…”
— Shauna Weatherly, FedSubK
Explore another company
Don’t see your company?

Enter your company name and we'll build the page.

Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →

Frequently asked questions

What federal contracts does Actelion Pharmaceuticals Us hold?

Actelion Pharmaceuticals Us (UEI H5BMHLMMNA28) shows $5.4M across 106 award actions in SCOUT’s public USASpending-backed profile, with Department of Veterans Affairs (VA) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.

How much in federal contracts does Actelion Pharmaceuticals Us have?

Actelion Pharmaceuticals Us shows $5.4M across 106 award actions. SCOUT tracks 1 incumbent recompetes ($407K) returning to market in the next 24 months.

Which agencies does Actelion Pharmaceuticals Us work with?

Actelion Pharmaceuticals Us’s firm-wide obligated mix is led by Department of Veterans Affairs (VA) (59%), Department of Justice (DOJ) (41%).

What is the UEI for Actelion Pharmaceuticals Us?

The Unique Entity ID (UEI) for Actelion Pharmaceuticals Us is H5BMHLMMNA28.

Does Actelion Pharmaceuticals Us have contracts coming up for recompete?

Yes — SCOUT tracks 1 incumbent recompete in the next 24 months (Low exposure). Open the recompete section on this page for PIID-level timing.

Ten of these with the durability read on each: the FY27 Sprint Pack, $2,800 through Sept 30.

The Pack is ten Pursuit Analyses in a 12-month balance. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

See Tactics on the pricing page

Scout Tactics is $290 a month, with the teaming tools on. It is not sold on this page.

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Sources: USASpending, FPDS, SAM.gov · Data shown is public-record; analysis by PrimeRFP SCOUT. Corpus refreshed Sep 10, 2026. Profile snapshot Aug 19, 2026.
primerfp.com/intel/company/actelion-pharmaceuticals-us-inc